2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2966

Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?
Abstract Number: 339

Assessment of High-Resolution Peripheral Quantitative Computed Tomography Parameters and Markers of Bone Metabolism in Community-Dwelling Elderly with and without Vertebral Fractures – the Sao Paulo Ageing & Health Study
Abstract Number: 2760

Assessment of Inflammatory Back Pain and Axial Spondyloarthritis in Brazil
Abstract Number: 2507

Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Abstract Number: 528

Assessment of Metacarpal Head Bone Microarchitecture According to Presence or Not of Inflammation in Rheumatoid Arthritis Patients with Low Disease Activity
Abstract Number: 1238

Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement
Abstract Number: 143

Assessment of Patient Satisfaction, Functionality and Quality of Life after Ultrasound Guided Knee Intervention: A Prospective Study Tejas Sheth, MD. Beverly Johnson, MD, MS. Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Abstract Number: 1582

Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
Abstract Number: 1663

Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis
Abstract Number: 2468

Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis
Abstract Number: 1556

Assessment of the Burden of Comorbidities By the Rheumatic Disease Comorbidity Index in Early Rheumatoid Arthritis Patients at Disease Onset
Abstract Number: 790

Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
Abstract Number: 1025

Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Abstract Number: 860

Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis
Abstract Number: 1534

Assessment of the Relationship of the Static and Dynamic Balance Parameters with Clinical, Functional and Radiological Findings in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].